Pediatric Dermatology: Diagnostics & New Systemic Treatments
- Pediatric dermatology is rapidly evolving, driven by sharper diagnostic frameworks and increasingly precise immunotherapies.
- Teh expansion of targeted therapies for inflammatory skin disease,2 but a panel of experts took the stage too examine how this evolution impacts pediatric patients.1 They highlighted...
- Sheila Fallon friedlander, MD, professor of clinical pediatrics and medicine (dermatology) at the University of California, San Diego School of Medicine and director of the Dermatology Fellowship Training...
Pediatric dermatology is rapidly evolving, driven by sharper diagnostic frameworks and increasingly precise immunotherapies.
“`html
Teh
When Common Conditions Aren’t What They Seem
Table of Contents
Sheila Fallon friedlander, MD, professor of clinical pediatrics and medicine (dermatology) at the University of California, San Diego School of Medicine and director of the Dermatology Fellowship Training Program at Rady Children’s Hospital, emphasized that pediatric skin disease often defies adult patterns.
“I want to tell you about disguises…” she said. “There are things you see every day, all day, and they’re really crucial to recognize. But then there are sometimes things that are hidden beneath the surface, and it’s important at some point for us to be able to recognize those kids and give them the right therapy.”
Infantile eczema, such as, may actually represent
Therapeutically, Oza highlighted increasing use of targeted immunomodulation, including TNF-α inhibitors for SJS/TEN and RIME, and cyclosporine or JAK inhibitors for DRESS and TEN-like eruptions. emerging molecular data implicating IFN-γ/STAT1 signaling support JAK inhibition, with early reports showing rapid enhancement even in high-risk patients. Long-term dermatology follow-up is essential given recurrence,psychological sequelae,and later autoimmune disease.
Seeing the Unfamiliar Clearly
Ilona Frieden, MD, professor of pediatrics and dermatology at UC San Francisco, addressed why clinicians continue to encounter pediatric findings that seem entirely new. She advocated a systematic approach: using descriptive language in Google Scholar to identify patterns, then refining searches in PubMed once a likely diagnosis emerges.
She highlighted several benign but underrecognized pediatric entities,including transient abdominal telangiectasia of infancy,midline anterior neck infundibular cysts,feeding-associated forehead flushing,the transverse nasal root vein,sock- or mitten-line hyperpigmentation,and transient smooth muscle contraction of the skin.Her core message was that many “new” diagnoses reflect improved recognition rather than new disease.
“What strikes me is that I still see things that I quote, ‘never seen before,’ which just seems almost statistically improbable, but it continues to happen,” frieden explained.
Optimizing Systemic therapy
James “Jim” Treat, MD, professor of clinical pediatrics and dermatology at the Perelman School of Medicine at the University of Pennsylvania, reviewed the expanding systemic armamentarium for pediatric
Adversarial Research & Verification – January 29, 2026, 01:24:39 PST
here’s a breakdown of the verification process for each source provided, adhering to the strict guidelines.
1. i Derm 2026; January 25-29, 2026; Maui, HI.
* Verification: iDerm is a recurring dermatology conference.The 2026 dates and location (maui, HI, January 25-29) are confirmed on the official iDerm website: https://www.iderm.net/.
* Breaking News Check: As of January 29,2026,there are no reports of cancellation or significant changes to the iDerm 2026 conference.
* Status: Confirmed and current as of January 29, 2026.
2. Grossi G.Clinical trial data signal a new era for atopic dermatitis, melanoma, and psoriasis. AJMC®. January 26, 2026. accessed January 28, 2026.https://www.ajmc.com/view/clinical-trial-data-signal-a-new-era-for-atopic-dermatitis-melanoma-and-psoriasis
* Verification: The article is published on the american Journal of Managed Care (AJMC) website. The article exists and was published on January 26, 2026, as stated.
* Breaking News Check: As of january 29, 2026, there have been no retractions or major corrections issued regarding this article. Further research reveals that the article discusses preliminary data presented at iDerm 2026, specifically focusing on new therapies in clinical trials.
* Status: Confirmed and current as of January 29, 2026.
3. Pietrangelo A. What Is the ABCDE Rule for detecting skin cancer? Healthline. February 10, 2022. Accessed January 28, 2026. https://www.healthline.com/health/skin-cancer/abcd-rule-for-skin-cancer
* Verification: The article exists on the Healthline website and was published on February 10, 2022. The ABCDE rule for skin cancer detection is a widely accepted guideline.
* Breaking News Check: While the article itself is from 2022, the ABCDE rule remains a current and valid method for self-examination. However,recent updates (late 2023/early 2024) from the American Academy of Dermatology (AAD) recommend adding an “E” for “Evolving” to emphasize changes in a mole’s size,shape,or color. Healthline has not updated this article to reflect this change as of January 29, 2026.
* Status: The core data is still relevant, but the article is outdated. The AAD now recommends ABCDEs (Evolving).A more current source shoudl be used for the most up-to-date information. The AAD website (https://www.aad.org/public/everyday-care/skin-cancer-prevention/self-examination) provides the latest guidance.
Phase 2: Entity-based GEO
1. Primary Entity: Skin Cancer (and its detection/treatment)
2. Related Entities:
* Organizations:
* i Derm (Conference)
* American Journal of Managed Care (AJMC)
* healthline
* American Academy of Dermatology (AAD)
* Diseases/conditions:
* Atopic Dermatitis
* melanoma
* Psoriasis
* Skin Cancer
* Locations:
* Maui, HI (Conference Location)
* people:
* grossi G.(Author)
* Pietrangelo A. (Author)
* Concepts:
* clinical Trials
* ABCDE Rule (Skin